



In the Claims

Please amend Claims 1-4 and 6-9, and add new Claims 12-23; as follows:

- 1. (Amended) A [monoclonal] recombinant antibody product, [characterized by an exchange of] comprising the V_H domain of the OKT3 antibody, wherein the cysteine [for another polar amino acid] at position H100A [the OKT3 antibody known under this name] of said V_H domain is substituted with a polar amino acid, wherein said position H100A is according to the Kabat numbering system.
- 2. (Amended) The [monoclonal] <u>recombinant</u> antibody <u>product</u>, characterized in that the polar amino acid is serine.
- 3. (Amended) The [monoclonal] <u>recombinant</u> antibody <u>product</u> according to claim 1[or 2, characterized in that it includes the sequence indicated in figure 2] <u>comprising the amino acid sequence depicted by SEQ ID NO: 2</u>.
- 4. (Amended) A method for the production of the [monoclonal] <u>recombinant</u> antibody <u>product</u> according to any one of claims 1 to 3, characterized by the steps of:
 - a) [obtainment of] <u>obtaining</u> mRNA from freshly subcloned hybridoma cells of OKT3 and transcription into cDNA,
 - b) [amplification of] amplifying the DNA coding for the variable domains of the light and heavy chains by means of PCR [using suitable primers],
 - cloning of the DNA obtained in b) into a vector adapted for site-specific mutagenesis as well as introduction of [the desired mutation using suitable primers,] a mutation in said position H100A of the V_H domain, wherein said position H100A is according to the Kabat numbering system, wherein said





- d) [insertion of] <u>inserting</u> the mutated DNA obtained in c) in an expression vector and expression in a suitable expression system.
- 5. (Reiterated) The method according to claim 4, wherein the primers used in step b) are Bi5, Bi8, Bi4 and Bi3f.
- 6. (Amended) The method according to claim 4 [or 5], wherein the vector used in step c) is pCR-Skript SK(+).
- 7. (Amended) The method according to [any one of claims 4 to 6] <u>claim 4</u>, wherein [the primer SK1 5'-GTAGTCAAGGCTGTAATGATCATC is used in step c)] <u>said cloning</u> uses a primer comprising the sequence depicted by SEQ ID NO: 7.
- 8. (Amended) The method according to [any one of claims 4 to 7] <u>claim 4</u>, wherein the expression vector used in step d) is pHOG21.
- 9. (Amended) The method according to [any one of claims 4 to 8] <u>claim 4</u>, wherein the expression takes place in XLl-Blue E. *coli* cells.

Please the following new claims:.

- --12. (New) The method according to claim 5, wherein the vector used in step c) is pCR-Skript SK(+).
- 13. (New) The method according to claim 5, wherein said cloning uses a primer comprising the sequence depicted by SEQ ID NO: 7.
- 14. (New) The method according to claim 6, wherein said cloning uses a primer comprising the sequence depicted by SEQ ID NO: 7.

- 15. (New) The method according to claim 5, wherein the expression vector used in step d) is pHOG21.
- 16. (New) The method according to claim 6, wherein the expression vector used in step d) is pHOG21.
- 17. (New) The method according to claim 7, wherein the expression vector used in step d) is pHOG21.
- 18. (New) The method according to claim 4, wherein the expression takes place in XLl-Blue E. *coli* cells.
- 19. (New) The method according to claim 5, wherein the expression takes place in XLl-Blue E. *coli* cells.
- 20. (New) The method according to claim 6, wherein the expression takes place in XLl-Blue E. *coli* cells.
- 21. (New) The method according to claim 7, wherein the expression takes place in XLl-Blue E. *coli* cells.
- 22. (New) The method according to claim 8, wherein the expression takes place in XLl-Blue E. *coli* cells.
- 23. (New) A peptide comprising the amino acid sequence depicted by SEQ ID NO: 2.
- 24. (New) An antibody comprising the peptide according to Claim 23.
- 25. (New) A single-chain antibody comprising the peptide according to Claim 23.